R&D Trends: Osteoporosis - Strong pipeline bodes well for future treatment

Description: Over the last 12 months, there have been encouraging developments in the osteoporosis pipeline, with new therapies either receiving regulatory approval or launching. Moreover, both in the clinical and preclinical pipeline, companies continue their quest to bring to market a new, safe, effective, and affordable anabolic drug to address unmet need in the osteoporosis market.

Features and benefits
- Understand key dynamics in the R&D pipeline for new osteoporosis therapies
- Benchmark novel and existing therapies using the target product profile identified by Datamonitor
- Support R&D decision making by evaluating osteoporosis clinical trial designs that have set a precedent, as well as analysis of discontinued projects
- Access The prediction of how the treatment landscape may change in the next 20 years

Highlights
- The osteoporosis pipeline remains well stocked, with several products continuing their clinical trials and no significant discontinuations. There most exciting novel candidates with new mechanisms of action continue to be the new antiresorptives cathepsin K inhibitors and the anti-sclerostin monoclonal antibodies anabolics.
- The osteoporosis treatment paradigm has been largely static for the past 20 years, but this trend is likely to change as new drugs reach the market. It is probable that the fracture prevention strategy will evolve from just focusing on increasing bone mineral density to improving the bone quality and strength.
- The major change in the treatment of osteoporosis will be the launch of new efficacious and safe anabolic treatments, allowing physicians to use these treatments earlier in the algorithm and in a wider category of patients. In particular companies are targeting the Wnt pathway, bone morphogenetic proteins, and insulin-like growth factor.

Your key questions answered
- What are the key trends in the osteoporosis pipeline?
- What is the clinical gold standard and how do new candidates have to compare to this to successfully penetrate the market?
- How will new osteoporosis treatments evolve in the next 20 years?
- What are the requirements of European and US regulatory bodies to ensure approval of a novel candidate?

Contents:
- Executive Summary
  - Strategic scoping and focus
  - Datamonitor key findings
  - Related reports

OVERVIEW
- Catalyst
- Summary

CLINICAL PIPELINE OVERVIEW
- Osteoporosis pipeline
  - The osteoporosis pipeline remains robust
  - Companies are focusing on developing anabolics as competition in the antiresorptive market increases
- Mechanism of action
- Late-stage development compounds recently discontinued
  [Missing title]

TARGET PRODUCT PROFILE
- Comparator therapies
  - Fosamax (alendronate; Merck & Co)
Target product profile versus current level of attainment

CLINICAL TRIAL DESIGN IN OSTEOPOROSIS
- Preclinical trials
  - Two different animal species tests are required by both the FDA and EMA
  - Preclinical trial design should reflect the clinical indication
- Clinical trials
  - The FDA and EMA have different patient inclusion requirements for osteoporosis trials
  - Clinical endpoints
- Future developments in clinical trial design
  - Trial endpoints unlikely to change

INNOVATIVE EARLY-STAGE APPROACHES
- New targets for osteoporosis treatments
  - Targets for antiresorptive treatment
  - Targets for anabolic treatment

THE FUTURE OF TREATMENT OF OSTEOPOROSIS
- Screening and osteoporosis diagnosis
  - Increased use of FRAX will lead to more osteoporosis prevention
- Change in treatment outcomes
  - Focusing on bone quality
- New treatment strategies
  - Anabolic treatments are likely to be used earlier in the treatment algorithm
  - Combination therapies
  - Personalized medicine

BIBLIOGRAPHY
- Journal papers
- Websites

APPENDIX
- Contributing experts
- Conferences attended
- Report methodology

Ordering:  
- Order Online - [http://www.researchandmarkets.com/reports/1652325/](http://www.researchandmarkets.com/reports/1652325/)
- Order by Fax - using the form below
- Order by Post - print the order form below and send to
  
  Research and Markets,
  Guinness Centre,
  Taylors Lane,
  Dublin 8,
  Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: R&D Trends: Osteoporosis - Strong pipeline bodes well for future treatment
Web Address: http://www.researchandmarkets.com/reports/1652325/
Office Code: SCD2ILP2

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 3800</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 9500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * _______________________
Job Title: _____________________________
Organisation: __________________________
Address: _______________________________
City: _________________________________
Postal / Zip Code: _____________________
Country: ______________________________
Phone Number: _________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World